FDA expands approval for AbbVie’s Skyrizi for active psoriatic arthritis
The FDA approval is based on data from two Skyrizi Phase III trials, KEEPsAKE-1 and KEEPsAKE-2.
January 26, 2022
by Pharmaceutical-Technology
Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events
The placebo effect is the well-known phenomenon of a person's physical or mental health improving after taking a treatment with no pharmacological therapeutic benefit - a sugar pill, or a syringe full of saline, for example.
January 20, 2022
by WorldPharmaNews
Tools4Patient Announces Name Change to Cognivia & Expands Board of Directors
Cognivia today announced a new name for the company formerly known as Tools4Patient, which provides clinical trials solutions based on AI / ML that account for individual patient personality traits...
January 6, 2022
by prnasia
Novavax’s COVID-19 vaccine highly effective in preventing disease
Recently published data suggests Novavax’s investigational COVID-19 vaccine, NVX-CoV2373, is 90 percent effective at preventing COVID-19 illness and 100 percent effective at preventing moderate-to-severe symptoms.
December 20, 2021
by EuropeanPharmaceuticalReview
Nasus Pharma Announces Clinical Data Demonstrating Efficacy of Taffix, Intranasal Antiviral Protection Against Common Cold and Upper Respiratory Infection
Nasus Pharma a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public health threats...
November 26, 2021
by Drugs
Crohn’s patients achieve 65 percent clinical remission with Tremfya®
Janssen has announced topline results from the Phase II GALAXI 1 clinical trial which showed rates of clinical remission – Crohn’s Disease Activity Index [CDAI]<150 – previously reported at week 12 increased at week...
November 18, 2021
by EuropeanPharmaceuticalReview
MDMA-assisted therapy successful in PTSD patients
Three sessions of MDMA-assisted talk therapy resulted in significant symptom reductions for 88 percent of patients with severe, chronic post-traumatic stress disorder (PTSD).
May 12, 2021
by europeanpharmaceuticalreview
Novavax allows giving COVID-19 vaccine to trial participants on placebo
Allowing volunteers to crossover to the active vaccine offers them an incentive to continue in the trials even when other authorised vaccines are available.
April 7, 2021
by expresspharma
Deception is not necessary for the placebo effect, finds new study
The study found that patients with irritable bowel syndrome taking open-label placebo reported similar improvements to those taking double-blind placebo.
April 2, 2021
by europeanpharmaceuticalreview
Positive effects of psychedelic microdosing likely due to placebo effect, finds study
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
March 4, 2021
by europeanpharmaceuticalreview
Peginterferon-lambda accelerates COVID-19 recovery, finds trial
Peginterferon-lambda rapidly reduced non-hospitalised COVID-19 patients’ viral loads and expedited their recovery in a Phase II study.
February 9, 2021
by europeanpharmaceuticalreview
Bamlanivimab Reduced Risk of COVID-19 at Nursing Homes in Phase 3 Trial
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company announced.
January 22, 2021
by americanpharmaceuticalreview